FDA refuses approval of Eli Lilly’s Alzheimer treatment

(Reuters) – Eli Lilly and Co stated that on Thursday, the U.S. Food and Drug Administration rejected the company’s experimental Alzheimer’s disease treatment. This was based on a small number of patients who provided data for at least 12 month of drug exposure.

(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)